Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Pediatr Blood Cancer. 2023 Mar 28;70(6):e30319. doi: 10.1002/pbc.30319

Figure 2: Participant Assessment of Safety and Utility of Various Treatments for Sickle Cell Disease.

Figure 2:

Using a five-point Likert Scale, participants were asked to rate the safety and utility of two potentially curative treatments for Sickle Cell Disease (SCD) (Gene Therapy, Bone Marrow Treatment) alongside two commonly utilized disease-modifying interventions (Hydroxyurea and Chronic Blood Transfusion Therapy).